Navigation Links
China Biologic's Guizhou Taibang Subsidiary Donates Lifesaving Plasma Products for the Injured in the Yunnan Earthquake
Date:9/10/2012

BEIJING, Sept. 10, 2012 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has donated 1000 bottles of Tetanus immunoglobulin through its Guizhou Taibang subsidiary for those injured in the devastating earthquake that struck in Yunnan Province, China on September 7, 2012. The donation was made to the quake-hit region on September 8.

Mr. David Gao, Chairman & CEO, said, "As a leading plasma-based biopharmaceutical company in China, we treat life with great respect.  It is part of our corporate social responsibility policy to help the needy when possible. We extend our condolence and best wishes to any families who have suffered through this tragedy and wish a prompt recovery for the quake-hit region and its people."

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2012, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:    

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Rob Koepp
Phone: +86-10-6583-7516 or +1-646-405-5191
E-mail: rob.koepp@icrinc.com

 


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QYresearchReports.com - Global and China Synthesis Polypeptide Drug Industry 2012 Deep Research Report
2. Arthroscopy Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
3. OncoSec Granted New Patent from China
4. China Botanic Receives New Patent on its Comprehensive Method to Enhance the Medicinal Value of Schisandra
5. China Nepstar Chain Drugstore Reports Second Quarter 2012 Financial Results
6. PRA Expands Operations in China
7. Pharma Manufacturing & Quality Management China 2012 is Upcoming
8. China Kanghui Holdings Reports Second Quarter 2012 Financial Results
9. The 2nd Pharma Logistics China 2012 will be Held in October
10. China Pharma Holdings, Inc. Reports Second Quarter 2012 Financial Results
11. Patient Monitoring Devices Market in Emerging Countries (China, India, Brazil) to 2017 - Increasing Government Spending and Foreign Direct Investment (FDI) to Drive Future Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. ... income of $18,800,000, or $0.45 per diluted share, on a ... first quarter ended October 31, 2016. This compares with net ... of $153,779,000 for the first quarter ended October 31, 2015. ... first quarter ended October 31, 2016 to $21,323,000, or $0.51 ...
(Date:12/8/2016)... , Dec. 8, 2016   Mederi Therapeutics Inc . has announced regulatory ... Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director ... , , "We are very ...
(Date:12/8/2016)... BEIJING , and SAN DIEGO , ... genomic services and solutions with cutting edge next-generation sequencing and ... biotechnology company; and the Genome Institute of ... (NovogeneAIT) – a new joint venture between Novogene and AITbiotech ... at Biopolis, Singapore .   ...
Breaking Medicine Technology:
(Date:12/7/2016)... Orleans, LA (PRWEB) , ... December 07, 2016 ... ... technique used to treat wrinkles and deep lines by smoothing and tightening the ... minimally invasive techniques out there to address facial aging with very little downtime, ...
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... to blow out his candles on his 14th birthday, Estefano Reano had only one wish: ... Joe DiMaggio Children’s Hospital surprised his family with a phone call that made his wish ... was playing at home, when we got the phone call telling us there was a ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):